Common deworming drug helps restore lung cancer's sensitivity to targeted therapy in mice
A form of lung cancer, which is found in about 10%–15% of Western patients and 40%–50% of Asian patients, is driven by a mutation in the epidermal growth factor receptor (EGFR) gene. Gefitinib is a go-to drug that shuts down this protein's signals. However, over time, cancer cells develop resistance to the drug and keep dividing even while treatment is underway, rendering gefitinib powerless. A…
Read original article on Medical Xpress - latest medical and health news stories →Related news
-
Rural women face higher death rates for breast cancer—and the gap is widening
United Kingdom
-
Nasal delivery of ALS treatment in tiny cell-made sacs delays disease onset in mice
United Kingdom
-
Skin has a sex: Females and males do not renew their skin in the same way
United Kingdom
-
HIV finds escape routes from a preventive antibody—but newer antibodies may close them
United Kingdom
-
AI could help predict which HPV infections progress to cancer
United Kingdom
-
Greater contact with nature linked to a more positive relationship with food
United Kingdom
-
Protein modification partially reverses cancer-related muscle wasting in preclinical study
United Kingdom
-
Engineers use AI, Reddit to identify potential side effects of unapproved new GLP-1
United Kingdom